Related Funds
Funds with similar focus
Fund Name | Location |
Asia Pacific Resources Development Investment | China, Hong Kong, Hong Kong Island |
BMO Harris Bank | Chicago, Illinois, United States |
Century Golden Resources Group | Beijing, Beijing, China |
Florac | France, Ile-de-France, Paris |
Hanhua Financial Holding | Beijing, Beijing, China |
Hanwha Investment Corp | Seoul, Seoul-t'ukpyolsi, South Korea |
HG Initiative | - |
Innovation Grade Capital | - |
Landstone Capital | Beijing, Beijing, China |
Microcap | - |
Picea Capital | Germany, Hamburg |
Raven Venture Partners | Austin, Texas, United States |
Scrum Software | Fukuoka, Fukuoka Prefecture, Japan |
TD Veen | Norway, Rogaland, Stavanger |
Treehouse Capital | California, Oakland, United States |
USAID East Africa Trade and Investment Hub | - |
Yipeng Zichan | China, Jiading District |
Yishi Medical Industry Investment Holdings | Beijing, Beijing, China |
Zhonghong Gold Control | Beijing, Beijing Shi, China |
ZopSmart | Bangalore, India, Karnataka |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
SyntaxBio | 17 Sep 2024 | Chicago, Illinois, United States | |||
Valar Labs | $22M | 30 May 2024 | Palo Alto, California, United States | ||
Latus Bio | $54M | 02 May 2024 | - | ||
Frontier Medicines | $80M | 22 Feb 2024 | San Francisco, California, United States | ||
Unlearn.AI | $50M | 08 Feb 2024 | San Francisco, California, United States | ||
Elo Life Systems | $20M | 24 Jan 2024 | Durham, North Carolina, United States | ||
Radionetics Oncology | $52M | 03 Jan 2024 | California City, California, United States | ||
Totus Medicines | $66M | 15 Dec 2023 | Cambridge, Massachusetts, United States | ||
CH4 Global | $29M | 29 Aug 2023 | Henderson, Nevada, United States |
– Stemson Therapeutics, a San Diego-based company, closed a $15m Series A financing.
– The round was led by DCVC Bio with participation from Genoa Ventures, AbbVie Ventures and other investors.
– The company intends to use the funds to advance development of its proprietary therapeutic solution to cure hair loss.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
SyntaxBio | 17 Sep 2024 | Chicago, Illinois, United States | |||
Valar Labs | $22M | 30 May 2024 | Palo Alto, California, United States | ||
Latus Bio | $54M | 02 May 2024 | - | ||
Frontier Medicines | $80M | 22 Feb 2024 | San Francisco, California, United States | ||
Unlearn.AI | $50M | 08 Feb 2024 | San Francisco, California, United States | ||
Elo Life Systems | $20M | 24 Jan 2024 | Durham, North Carolina, United States | ||
Radionetics Oncology | $52M | 03 Jan 2024 | California City, California, United States | ||
Totus Medicines | $66M | 15 Dec 2023 | Cambridge, Massachusetts, United States | ||
CH4 Global | $29M | 29 Aug 2023 | Henderson, Nevada, United States |